William Blair analyst Lachlan Hanbury Brown has reiterated their bullish stance on LENZ stock, giving a Buy rating today.
Lachlan Hanbury Brown has given his Buy rating due to a combination of factors that indicate a promising outlook for LENZ Therapeutics. The company has successfully completed its midcycle review with the FDA, with no significant issues noted, and the FDA has no plans to convene an Advisory Committee, suggesting a smooth path toward approval. This confidence is further supported by the company’s proactive steps in manufacturing and commercial preparations, indicating readiness for a potential launch later in the year.
Additionally, LENZ Therapeutics has made significant strides in its commercial readiness, hiring key sales leadership and receiving an overwhelming response for sales representative positions. Their EyeAmSelective awareness campaign has achieved substantial reach among eye care professionals, enhancing the company’s visibility and educational efforts. Moreover, positive Phase III study results from their partner in China reinforce the efficacy of their product, further supporting the Buy rating recommendation.
In another report released today, TD Cowen also maintained a Buy rating on the stock with a $60.00 price target.